公开(公告)号：US20200347050A1

公开(公告)日：2020-11-05

申请号：US16845594

申请日：2020-04-10

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Roch BOIVIN ,  Eric CARLSON ,  Atsushi ENDO ,  Hans HANSEN ,  Lynn D. HAWKINS ,  Sally ISHIZAKA ,  Matthew MACKEY ,  Sridhar NARAYAN ,  Takashi SATOH ,  Shawn SCHILLER

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  A61K31/55

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US20160176841A1

公开(公告)日：2016-06-23

申请号：US14908164

申请日：2014-10-14

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch BOIVIN ,  Hans HANSEN ,  Sally ISHIZAKA ,  Matthew MACKEY ,  Shawn SCHILLER ,  Chikako OGAWA ,  Sridhar NARAYAN ,  Peter BERTINATO ,  Gregory BERGER ,  Atsushi ENDO ,  Robert T. YU ,  Lynn HAWKINS

IPC: C07D401/02 ,  C07D413/14 ,  C07D471/04 ,  C07D401/14 ,  C07D417/14

CPC classification number: C07D401/02 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US20160326161A1

公开(公告)日：2016-11-10

申请号：US15220949

申请日：2016-07-27

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Eric CARLSON ,  Hans HANSEN ,  Lynn HAWKINS ,  Sally ISHIZAKA ,  Matthew MACKEY ,  Shawn SCHILLER ,  Chikako OGAWA ,  Heather DAVIS ,  Atsushi ENDO

IPC: C07D417/14 ,  C07D413/04 ,  C07D471/10 ,  C12Q1/68 ,  C07D493/10 ,  C07D487/04 ,  C07D451/04 ,  G01N33/50 ,  C07D413/14 ,  C07D487/10

Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US20180030045A1

公开(公告)日：2018-02-01

申请号：US15670904

申请日：2017-08-07

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： J. Eric CARLSON ,  Hans HANSEN ,  Lynn HAWKINS ,  Sally ISHIZAKA ,  Matthew MACKEY ,  Shawn SCHILLER ,  Chikako OGAWA ,  Heather DAVIS ,  Atsushi ENDO

IPC: C07D417/14 ,  C07D413/04 ,  C07D401/10 ,  C07D401/14 ,  C07D471/10 ,  C07D487/10 ,  C07D471/04 ,  C07D215/48 ,  C12Q1/68 ,  G01N33/50 ,  C07D451/04 ,  C07D487/04 ,  C07D493/10 ,  C07D413/14 ,  C07D403/14

CPC classification number: C07D417/14 ,  C07B2200/07 ,  C07D215/48 ,  C07D401/10 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D451/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D493/10 ,  C12Q1/6897 ,  G01N33/5023 ,  G01N33/5047

Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.